June 24, 2020 / 12:42 PM / 14 days ago

BRIEF-Chemocentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor Ccx559 For Next Generation Cancer Treatment

June 24 (Reuters) - ChemoCentryx Inc:

* CHEMOCENTRYX IDENTIFIES NOVEL ORALLY ADMINISTERED IMMUNE CHECKPOINT INHIBITOR CCX559 FOR NEXT GENERATION CANCER TREATMENT

* CHEMOCENTRYX INC - IDENTIFIED AN ORALLY ADMINISTERED CHECKPOINT INHIBITOR, CCX559, AND PLANS TO INITIATE CLINICAL DEVELOPMENT IN FIRST HALF OF 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below